">
Sunday, 5 April 2026
  
Login

Australia's most trusted
source of pharma news

Sunday, 05 April 2026
News

Founder scores emotional win

Posted 21 July 2025 PM

The first US site opening for Prescient Therapeutics’ lead drug candidate resulted in an emotional outpouring from the company’s Scientific Founder, Said Sebti, who described the launch as “one of the most exhilarating and humbling moments” of his career.

Last week, the Melbourne-based clinical stage oncology company announced it had completed the first site initiation visit in the US at the Virgina Commonwealth University (VCU) for its Phase 2 clinical trial of PTX-100 for patients with refractory/relapsed cutaneous T cell lymphoma.

To see the whole article, please login

Popular

Aussie pharma exec wins CEO job
Aussie GM exits but where to next?
Pharma unveils a new name
Novo's megastar notches a first
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home